Renibus Therapeutics® (“Renibus”), a clinical-stage biopharmaceutical company focusingon the prevention and treatment of cardiac, renal, and metabolic diseases, today announced its participation in Oppenheimer's 35th Annual Healthcare Life Sciences Conference, being held February 11-12, 2025, in a virtual format. Jeffrey Keyser, RPh, JD, PhD, President and CEO of Renibus, will present on Wednesday, February 12, 2025, at 10:40 am ET. Company management will also meet with investors in one-on-one meetings during the conference.
About Renibus Therapeutics
Renibus is a clinical stage biopharmaceutical company dedicated to treating, improving, and extending patients' lives by developing products to prevent disease progression, improve outcomes and protect against organ damage associated with cardio, renal and metabolic diseases. Renibus' first-in-a-new class lead program isRBT-1(stannic protoporfin / iron sucrose), a single dose IV drug that is given over 1-2 hours, 24-48 hours prior to patients undergoing elective cardiac and/or valve surgery. It is in a Phase 3 pivotal trial to reduce the risk of post operative complications and improve outcomes following cardiothoracic surgery. The drug has received FDA Breakthrough and Fast Track Designations.
Veverimer is an oral, non-absorbed hydrochloric acid binder that was acquired from Tricida. We are currently evaluating veverimer in preclinical models and analyzing historical data to further our understanding of its clinical profile with a goal of identifying an indication for evaluation in clinical trials. Renibus has three additional assets at earlier stages of development.
For more information, please visit the Company's website atwww.Renibus.comand engage with us on LinkedIn.
Investor and Media Contact:
Amy ConradJuniper Pointamy@juniper-point.com858-914-1962
Business Development Contact
Jamie DonadioCFO, Renibusjdonadio@renibus.com
https://mma.prnewswire.com/media/1938025/Renibus_Logo.jpg
https://c212.net/c/img/favicon.png?sn=LA11524&sd=2025-02-05
View original content to download multimedia:https://www.prnewswire.com/news-releases/renibus-to-present-at-oppenheimers-35th-annual-healthcare-life-sciences-conference-302369302.html
SOURCE Renibus Therapeutics
https://rt.newswire.ca/rt.gif?NewsItemId=LA11524&Transmission_Id=202502051605PR_NEWS_USPR_____LA11524&DateId=20250205